Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ALLO-316 |
| Synonyms | |
| Therapy Description |
ALLO-316 consists of allogeneic T-cells expressing a CD70-targeting chimeric antigen receptor (CAR), which potentially results in increased killing of tumor cells expressing CD70 and reduced tumor growth (Blood (2020) 136 (Supplement 1): 23). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ALLO-316 | ALLO 316|ALLO316 | CD70 Immune Cell Therapy 11 | ALLO-316 consists of allogeneic T-cells expressing a CD70-targeting chimeric antigen receptor (CAR), which potentially results in increased killing of tumor cells expressing CD70 and reduced tumor growth (Blood (2020) 136 (Supplement 1): 23). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04696731 | Phase I | ALLO-647 + Cyclophosphamide + Fludarabine ALLO-316 | Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma (TRAVERSE) | Active, not recruiting | USA | 0 |